Statements and panel consensus
| Number | Statement | CVI* | Agreement range | Mean | Consensus |
| Scenario 1. Low-level viremia during stable (≥6 months) first-line ART (≥2 consecutive HIV-1 RNA measurements 50–500 copies/mL) | |||||
| 1 | Immediate need to modify the ART regimen | 100 | 1–2 | 1.3 | Strong consensus against |
| 2 | Perform GRT | 82 | 2–5 | 4.3 | Strong consensus in favour |
| 3 | Assess adherence | 100 | 5 | 5 | Strong consensus in favour |
| 4 | Perform TDM | 58 | 2–5 | 3.4 | No consensus |
| 5 | Schedule an earlier follow-up | 100 | 4–5 | 4.8 | Strong consensus in favour |
| 6 | Evaluate chronic coinfections | 58 | 2–5 | 3.6 | No consensus |
| 7 | Assess inflammatory markers | 76 | 1–4 | 2.2 | Strong consensus against |
| 8 | Quantify HIV DNA in peripheral blood | 76 | 1–5 | 3.6 | Strong consensus in favour |
| Scenario 2. A viral blip during otherwise suppressive ART (a HIV-1 RNA measurement 50–1000 copies/mL with adjacent measurements<50 copies/mL) | |||||
| 1 | Immediate need to modify the ART regimen | 100 | 1–2 | 1.1 | Strong consensus against |
| 2 | Perform GRT | 100 | 1–2 | 1.6 | Strong consensus against |
| 3 | Assess adherence | 100 | 4–5 | 4.9 | Strong consensus in favour |
| 4 | Perform TDM | 82 | 1–4 | 1.9 | Strong consensus against |
| 5 | Schedule an earlier follow-up | 88 | 2–5 | 4.3 | Strong consensus in favour |
| 6 | Evaluate chronic coinfections | 47 | 1–5 | 3.2 | No consensus |
| 7 | Assess inflammatory markers | 100 | 1–2 | 1.5 | Strong consensus against |
| 8 | Quantify HIV DNA in peripheral blood | 64 | 1–4 | 2.2 | No consensus |
| Scenario 3. Low-level viral rebound during previously suppressive ART (≥2 consecutive HIV-1 RNA measurements 50–500 copies/mL) | |||||
| 1 | Immediate need to modify the ART regimen | 76 | 1–5 | 2.2 | Strong consensus against |
| 2 | Perform GRT | 100 | 4–5 | 4.9 | Strong consensus in favour |
| 3 | Assess adherence | 100 | 4–5 | 4.9 | Strong consensus in favour |
| 4 | Perform TDM | 58 | 2–5 | 3.6 | No consensus |
| 5 | Schedule an earlier follow-up | 88 | 2–5 | 4.4 | Strong consensus in favour |
| 6 | Evaluate chronic coinfections | 53 | 2–5 | 3.3 | No consensus |
| 7 | Assess inflammatory markers | 70 | 1–4 | 2.5 | Moderate consensus against |
| 8 | Quantify HIV DNA in peripheral blood | 58 | 2–5 | 3.4 | No consensus |
| Scenario 4. Residual viremia during suppressive ART (persistent HIV-1 RNA quantification below 50 copies/mL) | |||||
| 1 | Immediate need to modify the ART regimen | 94 | 1–5 | 1.3 | Strong consensus against |
| 2 | Perform GRT | 70 | 1–4 | 2.4 | Moderate consensus against |
| 3 | Assess adherence | 94 | 2–5 | 4.6 | Strong consensus in favour |
| 4 | Perform TDM | 64 | 1–5 | 2.4 | No consensus |
| 5 | Schedule an earlier follow-up | 70 | 2–5 | 3.8 | Moderate consensus in favour |
| 6 | Evaluate chronic coinfections | 41 | 1–5 | 3.2 | No consensus |
| 7 | Assess inflammatory markers | 64 | 1–4 | 2.4 | No consensus |
| 8 | Quantify HIV DNA in peripheral blood | 47 | 1–4 | 3.1 | No consensus |
Levels: 1, disagree; 2 somewhat disagree; 3 almost agree; 4, agree; 5, strongly agree.
*CVI expressed as %.
ART, antiretroviral therapy; CVI, content validity index; GRT, genotypic resistance testing; TDM, therapeutic drug monitoring.